Pneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation

Simple item page
dc.contributor.authorDemirdogen Cetinoglu E.
dc.contributor.authorUzaslan E.
dc.contributor.authorSayıner A.
dc.contributor.authorCilli A.
dc.contributor.authorKılınc O.
dc.contributor.authorSakar Coskun A.
dc.contributor.authorHazar A.
dc.contributor.authorKokturk N.
dc.contributor.authorFiliz A.
dc.contributor.authorPolatli M.
dc.contributor.authorTasbakan S.
dc.contributor.authorKaraboğa B.
dc.contributor.authorKilic Ö.
dc.contributor.authorHavlucu Y.
dc.contributor.authorTokgöz F.
dc.contributor.authorNazik S.
dc.date.accessioned2024-07-22T08:10:41Z
dc.date.available2024-07-22T08:10:41Z
dc.date.issued2017
dc.description.abstractBackground: Previous reports have shown that vaccination rates of adult at-risk populations are low in Turkey. There are differing reports with regards to the effectiveness of the influenza and the pneumococcal polysaccharide vaccine (PPSV23) on the clinical outcomes of community acquired pneumonia (CAP). The purpose of this study was to analyze the influenza (FV) and pneumococcal vaccination (PV) status, the factors that influence the receipt of influenza/pneumococcal vaccine and the effects of prior vaccination on the clinical outcomes in adults hospitalized with CAP. Patients and Methods: Patients hospitalized with CAP between March 2009 and October 2013 and registered at the web-based Turkish Thoracic Society Pneumonia Database (TURCAP) were included in this multicentric, observational study. Of a total of 787 cases, data were analyzed for 466 patients for whom self-reported information on PV and FV was available. Results: In this adult population with CAP, the vaccination rate with both the pneumococcal and influenza vaccines was found to be 6%. Prior FV was found to be the sole variable that was associated with the receipt of PV [OR 17.8, 95% CI (25–75:8.56–37.01), p < 0.001]. Conversely, being vaccinated with PPSV23 was the only predictor of receipt of FV [OR 18.1, 95% CI (25–75:8.75–37.83), p < 0.001]. Compared to the unvaccinated cases, the chest radiograms of the vaccinated patients revealed less consolidation. The latter also reported fatigue, muscle pain and gastrointestinal symptoms less frequently. Although there was a trend for lower 30-day mortality and for lower rates of intensive care unit (ICU) admission, these did not reach statistical significance. A pneumonia severity index (PSI) score ≥ 90, CURB-65 score ≥3 and multilobar involvement, but not the vaccination status, were identified as independent determinants of ICU admission. Conclusions: This study showed that, among patients hospitalized with CAP, the FV and/or PV rates are low. Prior vaccination does not appear to significantly affect the clinical outcomes. © 2017 Taylor & Francis.
dc.identifier.DOI-ID10.1080/21645515.2017.1339851
dc.identifier.issn21645515
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15350
dc.language.isoEnglish
dc.publisherTaylor and Francis Inc.
dc.rightsAll Open Access; Bronze Open Access; Green Open Access
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectCommunity-Acquired Infections
dc.subjectFemale
dc.subjectHospitalization
dc.subjectHumans
dc.subjectInfluenza Vaccines
dc.subjectInfluenza, Human
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPneumococcal Vaccines
dc.subjectPneumonia
dc.subjectPneumonia, Pneumococcal
dc.subjectRisk Factors
dc.subjectSeverity of Illness Index
dc.subjectStreptococcus pneumoniae
dc.subjectTurkey
dc.subjectVaccination
dc.subjectVaccination Coverage
dc.subjectYoung Adult
dc.subjectinfluenza vaccine
dc.subjectPneumococcus vaccine
dc.subject23-valent pneumococcal capsular polysaccharide vaccine
dc.subjectinfluenza vaccine
dc.subjectPneumococcus vaccine
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectchronic obstructive lung disease
dc.subjectclinical outcome
dc.subjectcommunity acquired pneumonia
dc.subjectfatigue
dc.subjectfemale
dc.subjectgastrointestinal symptom
dc.subjecthospital admission
dc.subjecthospitalization
dc.subjecthuman
dc.subjectinfluenza vaccination
dc.subjectintensive care unit
dc.subjectlength of stay
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmortality
dc.subjectmyalgia
dc.subjectobservational study
dc.subjectpneumococcal vaccination
dc.subjectPneumonia Severity Index
dc.subjectscoring system
dc.subjectthorax radiography
dc.subjectvaccination
dc.subjectvery elderly
dc.subjectadolescent
dc.subjectcommunity acquired infection
dc.subjecthospitalization
dc.subjectimmunology
dc.subjectinfluenza
dc.subjectmiddle aged
dc.subjectpneumonia
dc.subjectrisk factor
dc.subjectseverity of illness index
dc.subjectStreptococcus pneumonia
dc.subjectStreptococcus pneumoniae
dc.subjectvaccination
dc.subjectvaccination coverage
dc.subjectyoung adult
dc.titlePneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation
dc.typeArticle

Files

Collections

Scopus Koleksiyonu